A novel simple method to purify recombinant soluble human complement receptor type 1 (sCR1) from CHO cell culture

Biotechnology and Bioprocess Engineering

Volumn 7, Issue 2, 2002, Pages 67-75

  Kato, Hisamune ^a   Inoue, Takehiro ^a   Ishii, Noriyuki ^b   Murakami, Yoshinobu ^c   Matsumura, Masatoshi ^a   Seya, Tsukasa ^d   Wang, Pi Chao ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

C3b; Factor I; Necrosis; sCR1; Two stage cell culture method; Two stage protein purification method

Indexed keywords

EID: 0041323498     PISSN: 12268372     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02935882     Document Type: Article

References (47)

1. Klickstein, L. B., W. W. Wong, J. A. Smith, J. H. Weis, J. G. Wilson, and D. T. Fearon (1987) Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J. Exp. Med. 165: 1095-1112.
2. Klickstein, L. B., Bartow T. J., V. Miletic, L. D. Rabson, J. A. Smith, and D. T. Fearon (1988) Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J. Exp. Med. 168: 1699-1717.
3. Hourcade, D., D. R. Miesner, J. P. Atkinson, and V. M. Holers (1988) Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J. Exp. Med. 168: 1255-1270.
4. Weisman, H. F., T. Bartow, M. K. Leppo, H. C. Jr. Marsh, G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon (1990) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146-151.
5. Yeh, C. G., H. C. Jr. Marsh, G. R. Carson, L. Berman, M. E Concino, S. M. Scesney R. E. Kuestner, R. Skibbens, K. A. Donahue, and S. H. Ip (1991) Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats. J. Immunol. 146: 250-256.
6. Mulligan, M. S., C. G. Yeh, A. R. Rudolph, and P. A. Ward (1992) Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J. Immunol. 148: 1479-1485.
7. Pruitt, S. K., A. D. Kirk, R. R. Bollinger, H. C. Jr. Marsh, B. H. Collins, J. L. Levin, J. R. Mault, J. S. Heinle, S. Ibrahim, A. R. Rudolph (1994) The effect of soluble complement receptor type 1 on hyper-acute rejection of porcine xenografts. Transplantation 57: 363-370.
8. Jung, S., K. V. Toyka, and H. P. Hartung (1995) Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci. Lett. 200: 167-70.
9. Piddlesden, S. J., S. Jiang, J. L. Levin, A. Vincent, and B. P. Morgan (1996) Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 71: 173-177.
10. Mikata, S., S. Miyagawa, M. Yoshitatsu, M. Ikawa, M. Okabe, H. Matsuda, and R. Shirakura (1998) Prevention of hyperacute rejection by phosphatidylinositol- anchored mini-complement receptor type 1. Transpl. Immunol. 6: 107-110
11. Scesney, S. M., S. C. Makrides, M. L. Gosselin, P. J. Ford, B. M. Andrews, E. G. Hayman, and H. C. Jr. Marsh (1996) A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway. Eur. J. Immunol. 16: 1729-1735.
12. Rittershaus, C. W., L. J. Thomas, D. P. Miller, M. D. Picard, K. M. Geoghegan-Barek, S. M. Scesney, L. D. Henry, A. C. Sen, A. M. Bertino, G. Hannig, H. Adari, R. A. Mealey M. L. Gosselin, M. Couto, E. G. Hayman, J. L. Levin, V. N. Reinhold, and H. C. Jr. Marsh (1999) Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J. Biol. Chem. 274: 11237-11244.
13. Wong, W. W. and S. A. Farrell (1991) Proposed structure of the F′ allotype of human CR1. Loss of a C3b binding site may be associated with altered function. J. Immunol. 146: 656-662
14. Seya, T., M. Matsumoto, M. Hatanaka, M. Okada, T. Masaki, and K. Iida (1996) Rapid purification of human complement receptor type 1 (CD35, CR1). J. Biochem. Biophys. Methods. 32: 69-76.
15. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
16. Dykman, T. R., J. A. Hatch, M. S. Aqua, and J. P. Atkinson (1985) Polymorphism of the C3b/C4b receptor (CR1): characterization of a fourth allele. J. Immunol. 134: 1787-1789.
17. Carron, J. A., R. C. Bates, A. I. Smith, T. Tetoz, A. Arellano, D. L. Gordon, and G. E Burns (1996) Factor H co-purifies with thrombospondin isolated from platelet secretate. Biochim. Biophys. Acta 1289: 305-311.
18. Honda, J., H. Andou, T. Mannen, and S. Sugimoto (2000) Direct refolding of recombinant human growth differntiation factor 5 for large-scale production process. J. Biosci. Bioeng. 89: 582-589.
19. Birmingham, D. J., X. P. Shen, D. Hourcade, M. W. Nickells, and J. P. Atkinson (1994) Primary sequence of an alternatively spliced form of CR1. Candidate for the 75, 000 M(r) complement receptor expressed on chimpanzee erythrocytes. J. Immunol. 153: 691-700.
20. Nickells, M., R. Hauhart, M. Krych, V. B. Subramanian, K. Geoghegan-Barek, H. C. Jr. Marsh, and J. P. Atkinson (1998) Mapping epitopes for 20 monoclonal antibodies to CR1. Clin. Exp. Immunol. 112: 27-33.
21. Hack, C. E., J. Paardekooper, and F. Van Milligen (1990) Demonstration in human plasma of a form of C3 that has the conformation of "C3b-like C3". J. Immunol. 144: 4249-4255.
22. Seya, T., M. Okada, K. Hazeki, and S. Nagasawa (1991) Regulatory system of guinea-pig complement C3b: tests for compatibility of guinea-pig factors H and I with human factors. Mol. Immunol. 28: 375-382.
23. Mevorach, D., J. O. Mascarenhas, D. Gershov, and K. B. Elkon (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J. Exp. Med. 188: 2313-2320.
24. Carrington, C. A. and G. dos Santos Cruz (2001) Effect of cell surface concentration of human DAF on transgenic pig aortic endothelial cells on the degree of protection afforded against human complement deposition. Xenotransplantation 8: 100-105.
25. Huang, J., D. Gou, C. Zhen, D. Jiang, X. Mao, W. Li, S. Chen, and C. Cai (2001) Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCE FEMS Immunol. Med. Microbiol. 31: 203-209.
26. Umeda, M. (1991) Cultivation of mammalian cells in serum-free media. Hum. Cell. 4: 285-290.
27. Fukaya, K., S. Asahi, S. Nagamori, M. Sakaguchi, C. Gao, M. Miyazaki, and M. Namba (2001) Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1 and 1A2 activities from fetal liver tissue by transfection of SV40 LT. In Vitro Cell Dev. Biol. Anim. 37: 266-269.
28. Jang, J. H., F. Wang, and M. Kan (1997) Heparan sulfate is required for interaction and activation of the epithelial cell fibroblast growth factor receptor-2IIIb with stromal-derived fibroblast growth factor-7. In Vitro Cell Dev. Biol. Anim. 33: 819-824.
29. Fujikawa, K., H. Suzuki, B. McMullen, and D. Chung (2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98: 1662-1666.
30. Rosenberg, R. D., N. W. Shworak, J. Liu, and L. Zhang (1997) Heparan Sulfate Proteoglycans of the Cardiovascular System. J. Clin. Invest. 99: 2062-2070.
31. Kurumiya, Y., Y. Nimura, E. Takeuchi, K. Nozawa, M. Nagino, A. Hayata, A. Maeda, and S. Yoshida (1999) Active form of human hepatocyte growth factor is excreted into bile after hepatobiliary resection. J. Hepatol. 30: 22-28.
32. Garke, G., W. D. Deckwer, and F. B. Anspach (2000) Preparative two-step purification of recombinant human basic fibroblast growth factor from high-cell-density cultivation of Escherichia coli. J. Chromatogr. B. Biomed. Sci. Appl. 737: 25-38.
33. Koyama, N., H. Ohmae, S. Tsuji, Y. Tanaka, T. Kurokawa, and O. Nishimura (2001) Improved preparation and crystallization of 25 kDa human fibroblast growth factor-9. Biotechnol. Appl. Biochem. 33: 117-121.
34. Seya, T., V. M. Holers, and J. P. Atkinson (1985) Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF). J. Immunol. 135: 2661-2667.
35. Moen, O., K. Hogasen, E. Fosse, E. Dregelid, V. Brockmeier, P. Venge, M. Harboe, and T. E. Mollnes (1997) Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann. Thorac. Surg. 63: 105-111.
36. Saito, N., S. Motoyama, and J. Sawamoto (2000) Effects of new polymer-coated extracorporeal circuits on bio-compatibility during cardiopulmonary bypass. Artif. Organs 24: 547-554.
37. Skerl, K. G., R. A. Calderone, T. Sreevalsan, J. Burge, A. Nicholson-Weller, and K. F. Austen (1981) Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase. J. Immunol. 126: 232-235.
38. Kaidoh, T., S. Natsuume-Sakai, and M. Takahashi (1981) Murine C4-binding protein: a rapid purification method by affinity chromatography. J. Immunol. 126: 463-467.
39. Ram, S., M. Cullinane, A. M. Blom, S. Gulati, D. P. McQuillen, R. Boden, B. G. Monks, C. O'Connell, C. Elkins, M. K. Pangburn, B. Dahlback, and P. A. Rice (2001) C4bp binding to porin mediates stable serum resistance of Neisseria gonorrhoeae. Int. Immunopharmacol. 1: 423-432.
40. Carron, J. A., R. C. Bates, A. I. Smith, T. Tetoz, A. Arellano, D. L. Gordon, and G. F. Burns (1996) Factor H co-purifies with thrombospondin isolated from platelet secretate. Biochim. Biophys. Acta 1289: 305-311.
41. Scott, P. E., D. B. Purkall, and S. Ruddy (1997) Effects of thrombospondin purified by heparin affinity or ion-exchange chromatography on the alternative complement pathway. J. Immunol. Methods. 202: 213-216.
42. Henry, S. P., P. C. Giclas, J. Leeds, M. Pangburn, C. Auletta, A. A. Levin, and D. J. Kornbrust (1997) Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J. Pharmacol. Exp. Ther. 281: 810-816.
43. Lopez-Trascasa, M., D. H. Bing, M. Rivard, and A. Nicholson-Weller (1989) Factor J: Isolation and characterization of a new polypeptide inhibitor of complement C1. J. Biol. Chem. 264: 16214-16221.
44. Diamond, M. S., R. Alon, C. A. Parkos, M. T. Quinn, and T. A. Springer (1995) Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J. Cell Biol. 130: 1473-1482.
45. Peter, K., M. Schwarz, C. Conradt, T. Nordt, M. Moser, W. Kubler, and C. Bode (1999) Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Circulation. 100: 1533-1539.
46. Sinitsyn, V. V., E. T. Bokchubaev, A. G. Mamontova, N. V. Ovtrakht, E. L. Nasonov, G. A. Konovalov, and V. V. Kukharchuk (1992) C3a and C5a anaphylatoxins bind to heparin-based sorbent in low density lipoprotein apheresis: in vitro and in vivo investigations. Artif. Organs 16: 291-293.
47. Lidington, E. A., D. O. Haskard, and J. C. Mason (2000) Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 96: 2784-2792.